Skip to main content
padlock icon - secure page this page is secure

Review of Chemoradiotherapy for High-Risk Prostate Cancer

Buy Article:

$63.00 + tax (Refund Policy)

While most newly-diagnosed prostate cancers are well-differentiated tumors that have high probability of cure, there is a subset of patients that present with aggressive malignancies that have significant potential for recurrence and metastasis. Single-modality treatment approaches have demonstrated relatively high failure rates, and multimodality therapy (radiation therapy and hormonal ablation therapy) has become standard of care for these patients. These treatments are not without toxicity, and a significant percentage of patients will become refractory to hormonal therapy.

Historically, radiation therapy of prostate cancer was associated with significant genitourinary and gastrointestinal morbidity. With advances in radiation therapy techniques and delivery, the potential for safe dose-escalation has emerged. Further, there is an opportunity for chemotherapeutic agents to play an important syngergistic role in radiosensitizing the tumor cells at the primary site while also addressing micrometastatic disease. Concurrent chemoradiation therapy has become standard treatment for many types of locally advanced tumors, including lung, cervical, esophageal, rectal, and anal malignancies. We present a review of clinical trials examining the role of chemoradiation therapy in high-risk prostate cancer.



No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Cancer; DOCETAXEL; Estramustine phosphate; IMRT; Image-Guided Radiation Therapy (IGRT); PACLITAXEL; T4 prostatic adenocarcinoma; Three-Dimensional Conformal Radiotherapy (3DCRT); Vinblastine; chemotherapy; concurrent; cytotoxic anti-microtubule agent; depolymerization; high-risk; plasma testosterone levels; prostate; radiotherapy; tubulin; vinca alkaloid

Document Type: Research Article

Publication date: January 1, 2011

More about this publication?
  • Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I - IV clinical trial studies, clinical investigations at all stages of development and therapeutics.

    The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more